CannaPharmaRX Changes Auditors to EisnerAmper LLP
Ticker: CPMD · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1081938
| Field | Detail |
|---|---|
| Company | Cannapharmarx, Inc. (CPMD) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
CannaPharmaRX swapped auditors from Dale & Associates to EisnerAmper LLP, effective Nov 20, 2024.
AI Summary
CannaPharmaRX, Inc. filed an 8-K on November 20, 2024, to report a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, Dale & Associates, CPAs, P.A., and has appointed EisnerAmper LLP as its new auditor. This change was approved by the Audit Committee of the Board of Directors.
Why It Matters
A change in auditors can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence and financial reporting scrutiny.
Risk Assessment
Risk Level: medium — A change in auditors, especially without a clear stated reason beyond routine, can sometimes precede or coincide with other significant corporate events or financial restatements.
Key Players & Entities
- CannaPharmaRX, Inc. (company) — Registrant
- Dale & Associates, CPAs, P.A. (company) — Former Certifying Accountant
- EisnerAmper LLP (company) — New Certifying Accountant
- November 20, 2024 (date) — Date of earliest event reported
FAQ
When was the change in certifying accountant effective?
The change in certifying accountant was effective as of November 20, 2024.
Who was CannaPharmaRX's former independent auditor?
CannaPharmaRX's former independent auditor was Dale & Associates, CPAs, P.A.
Who is CannaPharmaRX's new independent auditor?
CannaPharmaRX has appointed EisnerAmper LLP as its new independent registered public accounting firm.
Did the former auditor report any disagreements with CannaPharmaRX?
The filing states that there were no disagreements between CannaPharmaRX and Dale & Associates, CPAs, P.A. on any matter of accounting principles or practices or financial statement disclosure.
Who approved the appointment of the new auditor?
The appointment of EisnerAmper LLP was approved by the Audit Committee of the Board of Directors of CannaPharmaRX, Inc.
Filing Stats: 712 words · 3 min read · ~2 pages · Grade level 13.5 · Accepted 2024-11-21 13:47:27
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CPMD OTC Markets Indicat
Filing Documents
- canna_8k.htm (8-K) — 29KB
- canna_ex991.htm (EX-99.1) — 3KB
- canna_ex991img1.jpg (GRAPHIC) — 3KB
- canna_ex991img2.jpg (GRAPHIC) — 4KB
- 0001654954-24-014753.txt ( ) — 169KB
- isdr-20241120.xsd (EX-101.SCH) — 6KB
- isdr-20241120_lab.xml (EX-101.LAB) — 15KB
- isdr-20241120_cal.xml (EX-101.CAL) — 1KB
- isdr-20241120_pre.xml (EX-101.PRE) — 9KB
- isdr-20241120_def.xml (EX-101.DEF) — 2KB
- canna_8k_htm.xml (XML) — 4KB
01 Change in Registrant's Certifying Accountant
Item 4.01 Change in Registrant's Certifying Accountant. (a) Resignation of Previous Independent Registered Public Accounting Firm On Thursday November 14, 2024, CannaPharmaRX, Inc.'s (the "Company", "we", "us", "our") auditor, GreenGrowth CPAs ("GreenGrowth") resigned from their engagement as our auditor effective November 14, 2024. GreenGrowth has served as our independent registered public accounting firm since 2023. Since our engagement with GreenGorwth, (i) there were no disagreements between the Company and GreenGrowth on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to GreenGrowth's satisfaction, would have caused GreenGrowth to make reference in connection with its opinion to the subject matter of the disagreement, and (ii) there were no "reportable events," as that term is described in Item 304(a)(1)(v) of Regulation S-K. The report of GreenGrowth to our financial statements for fiscal year ending December 31, 2023 included in our Annual Report on Form 10-K for the year ended December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principle. The report had been prepared assuming that we would continue as a going concern and included an explanatory paragraph regarding our ability to continue as a going concern as result of recurring loses from operations, a significant accumulated deficit and consistent negative cash flows. We have provided GreenGrowth with a copy of the foregoing disclosures we are making in this Current Report on Form 8-K prior to its filing and requested, in accordance with applicable practices, that GreenGrowth furnish a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made herein. Attached as Exhibit 9.01 is a copy of GreenGrowth's letter, dated November 14, 2024 s
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 9.01 Letter from GreenGrowth CPAs, dated November 20, 2024 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CANNAPHARMARX, INC. November 20, 2024 By: /s/ Rick Orman Name: Rick Orman Title: Chairman 3